Oral hypoglycemic agents for gestational diabetes mellitus?
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Gestational diabetes mellitus (GDM), the most frequent medical complication of pregnancy, is associated with several adverse outcomes over the short- and long-term for both mother and offspring. Standard treatment for GDM consists of insulin injections. Oral hypoglycemic agents (OHAs), on the other hand, are still the subject of controversy. Although OHAs are seemingly as efficient as insulin and may provide better quality of life, congenital malformations and unknown long-term effects are still feared. AREAS COVERED: Recent data on the pharmacokinetics of two OHAs (glyburide and metformin) and their clinical use for GDM are reviewed, with a focus on clinical trials and observational studies comparing insulin with glyburide or metformin (1960 - 2010). The review will provide a comprehensive overview of the pros and cons of OHA usage, an appreciation of OHAs' efficiency for the purpose of controlling glycemia and embryogenetic basics relating to congenital malformations. EXPERT OPINION: While insulin treatment is an effective therapy for controlling maternal glycemia, it nevertheless requires sufficient education and skills on the part of the patient to manage properly and may cause hypoglycemia, fear and anxiety. Oral treatment as a more user-friendly alternative may thus facilitate the control of GDM in some patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Gestational Diabetes and the Incidence of Type 2 Diabetes
Kim, C., Newton, K. M., & Knopp, R. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1862 · Cited by 2,276
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 1×
“Today, many of these complications can either be treated and/or prevented [3-7] and GDM now appears as a distinct entity with serious long-term consequences for both the mother and the child to be born.”
BackgroundMetzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 6×
“However, the MiG trial [7] study was not taken into account in these reports.”
BackgroundMethodInfluentialDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 4×
“For glyburide, aside from the Langer study [5] (4% failure), two small retrospective studies (n = 95 and 69) among Hispanic women revealed that the respective 19 and 21% failure rates were related to maternal age, early diagnosis (< 25 weeks), multiparity and higher fasting glucose levels, suggesting that many of thes…”
BackgroundMethodInfluentialAmerican Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s88 · Cited by 916
Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus
Butte, N. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1256s · Cited by 826
Clausen, T. D., Mathiesen, E. R., Hansen, T., Pedersen, O., Jensen, D. M., Lauenborg, J., & Damm, P. (2008) · Diabetes Care · doi:10.2337/dc07-1596 · Cited by 724 · cited 1×
“Indeed, during pregnancy, different environmental effects attributable to maternal obesity, hyperglycemia and insulin resistance, the so-called epigenetic factors, may induce longterm effects on the fetus [15-17].”
BackgroundGestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677 · cited 1×
“Today, many of these complications can either be treated and/or prevented [3-7] and GDM now appears as a distinct entity with serious long-term consequences for both the mother and the child to be born.”
BackgroundChildhood Obesity and Metabolic Imprinting
Hillier, T. A., Pedula, K. L., Schmidt, M. M., Mullen, J. A., Charles, M.-A., & Pettitt, D. J. (2007) · Diabetes Care · doi:10.2337/dc06-2361 · Cited by 656
Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes
Catalano, P. M., Tyzbir, E. D., Wolfe, R. R., Calles, J., Roman, N. M., Amini, S. B., & Sims, E. A. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.1.e60 · Cited by 484 · cited 1×
“The first phase is insulin resistance, due to changes in the hormonal environment of pregnancy, followed by a second phase characterized by a deficiency of pancreatic b cells to respond with sufficient insulin secretion [29-31].”
BackgroundClausen, T. D., Mathiesen, E. R., Hansen, T., Pedersen, O., Jensen, D. M., Lauenborg, J., Schmidt, L., & Damm, P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0305 · Cited by 453
Risk of development of diabetes mellitus after diagnosis of gestational diabetes
Feig, D. S., Zinman, B., Wang, X., & Hux, J. E. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080012 · Cited by 440 · cited 1×
“On the long term, the mother is at high risk of type 2 diabetes mellitus (T2DM) and 70% are afflicted within 25 years postpartum [8]; in Canada, the rate of diagnosis was shown to reach almost 20% every 9 years [9].”
BackgroundBaillargeon, J.-P., Jakubowicz, D. J., Iuorno, M. J., Jakubowicz, S., & Nestler, J. E. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.127 · Cited by 300 · cited 1×
“The duration of metformin therapy before achieving pregnancy was variable within and among studies because the duration of therapy that is required in order to become pregnant is variable [17,55-57].”
BackgroundSelf-citationPregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274 · cited 4×
“Clinical data are also reassuring as teratogenicity was not increased in women with type 2 diabetes [27] and PCOS [58-61] who were using metformin before conception and continued it during pregnancy.”
BackgroundInfluentialEffect of treatment of gestational diabetes mellitus on obesity in the next generation
Gillman, M. W., Oakey, H., Baghurst, P. A., Volkmer, R. E., Robinson, J. S., & Crowther, C. A. (2010) · Diabetes Care · doi:10.2337/dc09-1810 · Cited by 269 · cited 1×
“frequently and more rapidly than children born from normal pregnancy [11-13], although this is still a matter of debate [14].”
BackgroundHwang, H., Bowen, B. P., Lefort, N., Flynn, C. R., De Filippis, E. A., Roberts, C., Smoke, C. C., Meyer, C., Højlund, K., Yi, Z., et al. (2010) · Diabetes · doi:10.2337/db09-0214 · Cited by 255
Hebert, M., Ma, X., Naraharisetti, S., Krudys, K., Umans, J., Hankins, G., Caritis, S., Miodovnik, M., Mattison, D., Unadkat, J., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.5 · Cited by 252 · cited 9×
“Insulin therapy, obviously, remediates both of these etiologies, but it is also logical to consider using modern OHAs which were designed for T2DM treatment.”
BackgroundResultInfluentialPlacental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Pirkola, J., Pouta, A., Bloigu, A., Hartikainen, A.-L., Laitinen, J., Järvelin, M.-R., & Vääräsmäki, M. (2010) · Diabetes Care · doi:10.2337/dc09-1871 · Cited by 214 · cited 1×
“frequently and more rapidly than children born from normal pregnancy [11-13], although this is still a matter of debate [14].”
BackgroundPharmacokinetics of metformin during pregnancy
Eyal, S., Easterling, T. R., Carr, D., Umans, J. G., Miodovnik, M., Hankins, G. D. V., Clark, S. M., Risler, L., Wang, J., Kelly, E. J., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031245 · Cited by 209
Jacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177
Chmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118 · cited 2×
“For glyburide, aside from the Langer study [5] (4% failure), two small retrospective studies (n = 95 and 69) among Hispanic women revealed that the respective 19 and 21% failure rates were related to maternal age, early diagnosis (< 25 weeks), multiparity and higher fasting glucose levels, suggesting that many of thes…”
BackgroundResultMetformin compared with glyburide for the management of gestational diabetes
Silva, J. C., Pacheco, C., Bizato, J., de Souza, B. V., Ribeiro, T. E., & Bertini, A. M. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.04.028 · Cited by 115 · cited 3×
“2%) in one study [66], although no difference was reported in the second study [67].”
BackgroundResultMetformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Hemauer, S. J., Patrikeeva, S. L., Nanovskaya, T. N., Hankins, G. D. V., & Ahmed, M. S. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.01.035 · Cited by 103 · cited 4×
“Because transporter-mediated efflux is a determinant of placental transfer, drug--drug interactions involving the process of transporter-mediated efflux could affect the extent of fetal exposure to medications [34].”
BackgroundInfluentialLain, K. Y., Garabedian, M. J., Daftary, A., & Jeyabalan, A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.02.038 · Cited by 100 · cited 1×
“9% increase in the rate of intrauterine growth retardation [72].”
BackgroundTransfer of metformin across the dually perfused human placental lobule
Nanovskaya, T. N., Nekhayeva, I. A., Patrikeeva, S. L., Hankins, G. D. V., & Ahmed, M. S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.047 · Cited by 98 · cited 1×
“However, the placental tissue only retains a small amount of metformin (< 20% of the maternal circulation) mostly residing in the extracellular space [51].”
BackgroundPredictors of glyburide failure in the treatment of gestational diabetes
Kahn, B. F., Davies, J. K., Lynch, A. M., Reynolds, R. M., & Barbour, L. A. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000218704.28313.36 · Cited by 85
Rochon, M., Rand, L., Roth, L., & Gaddipati, S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.07.029 · Cited by 82
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Salvesen, K. Å., Vanky, E., & Carlsen, S. M. (2007) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.3965 · Cited by 48 · cited 4×
“Clinical data are also reassuring as teratogenicity was not increased in women with type 2 diabetes [27] and PCOS [58-61] who were using metformin before conception and continued it during pregnancy.”
BackgroundInfluentialRamos, G. A., Jacobson, G. F., Kirby, R. S., Ching, J. Y., & Field, D. R. (2007) · Journal of Perinatology · doi:10.1038/sj.jp.7211683 · Cited by 44 · cited 1×
“5) and hypoglycemia (34 vs 14%) were increased with glyburide treatment in three studies including only 54, 122 and 68 women, respectively [43-45].”
BackgroundSuitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome
Gagnon, C., & Baillargeon, J.-P. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060607 · Cited by 33
Self-citation
Cited by
Metformin vs insulin in the management of gestational diabetes: a meta-analysis
Gui, J., Liu, Q., & Feng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064585 · Cited by 222
“GDM, the most frequent medical complication of pregnancy, is associated with several adverse outcomes over the short- and long-term for both mother and offspring [2].”
BackgroundLautatzis, M.-E., Goulis, D. G., & Vrontakis, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.006 · Cited by 113
Izadi, V., Tehrani, H., Haghighatdoost, F., Dehghan, A., Surkan, P. J., & Azadbakht, L. (2016) · Nutrition · doi:10.1016/j.nut.2016.03.006 · Cited by 108
The use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76
Metadata
- Authors
- Maymone, A. C., Baillargeon, J.-P., Ménard, J., & Ardilouze, J.-L.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2011-01-06
- Volume
- 10
- Issue
- 2
- Pages
- 227-238
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2097906965
- Cited by
- 41
- References
- 38
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.